Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanja Fehm

Showing results (331-340 of 371) with videos related to

Pageof 38
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 13, 2016
Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter studyLinn Woelber, Lis-Femke Griebel, Christine Eulenburg, et al.
Geburtshilfe Und Frauenheilkunde|December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
International Journal of Cancer|May 14, 2019
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillanceChristoph Engel, Christine Fischer, Silke Zachariae, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
The Oncologist|March 12, 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Jean-Yves Pierga, James M Reuben, et al.
Cell Reports. Medicine|November 20, 2024
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCarsten Denkert, Andreas Schneeweiss, Julia Rey, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2021
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysisAndreas D Hartkopf, Sara Y Brucker, Florin-Andrei Taran, et al.
Pageof 38

Showing results (331-340 of 371) with videos related to

Sort By:
Pageof 38
European Journal of Cancer (Oxford, England : 1990)|November 13, 2016
Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter studyLinn Woelber, Lis-Femke Griebel, Christine Eulenburg, et al.
Geburtshilfe Und Frauenheilkunde|December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
International Journal of Cancer|May 14, 2019
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillanceChristoph Engel, Christine Fischer, Silke Zachariae, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
The Oncologist|March 12, 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Jean-Yves Pierga, James M Reuben, et al.
Cell Reports. Medicine|November 20, 2024
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCarsten Denkert, Andreas Schneeweiss, Julia Rey, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2021
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysisAndreas D Hartkopf, Sara Y Brucker, Florin-Andrei Taran, et al.
Pageof 38